Zoetis Inc. (NYSE:ZTS) Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 62.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 82,878 shares of the company’s stock after selling 140,739 shares during the period. Gabelli Funds LLC’s holdings in Zoetis were worth $14,368,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its holdings in Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares during the last quarter. Sarasin & Partners LLP grew its stake in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after buying an additional 1,904,899 shares in the last quarter. Swedbank AB purchased a new stake in shares of Zoetis in the 1st quarter valued at $210,815,000. Public Employees Retirement Association of Colorado acquired a new position in Zoetis during the 4th quarter worth about $242,757,000. Finally, CIBC Private Wealth Group LLC boosted its holdings in Zoetis by 122.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock valued at $285,923,000 after acquiring an additional 797,884 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.5 %

NYSE ZTS opened at $193.59 on Tuesday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a 50 day moving average of $185.01 and a two-hundred day moving average of $174.42. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $88.33 billion, a PE ratio of 37.30, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter last year, the company earned $1.41 EPS. The business’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, research analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent research reports. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus upped their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $220.38.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.